TY - JOUR
T1 - Human skin culture as an Ex vivo model for assessing the fibrotic effects of insulin-like growth factor binding proteins
AU - Yasuoka, Hidekata
AU - Larregina, Adriana T.
AU - Yamaguchi, Yukie
AU - Feghali-Bostwick, Carol A.
N1 - Publisher Copyright:
© 2019, Bentham Science Publishers B.V.. All rights reserved.
PY - 2008
Y1 - 2008
N2 - Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. A hallmark of SSc is fibrosis of the skin and internal organs. We recently demonstrated increased expression of IGFBP-3 and IGFBP-5 in primary cultures of fibroblasts from the skin of patients with SSc. In vitro, IGFBP-3 and IGFBP-5 induced a fibrotic phenotype and IGFBP-5 triggered dermal fibrosis in mice. To assess the ability of IGFBPs to trigger fibrosis, we used an ex vivo human skin organ culture model. Our findings demonstrate that IGFBP-3 and IGFBP-5, but not IGFBP-4, increase dermal and collagen bundle thickness in human skin explants, resulting in substantial dermal fibrosis and thickening. These fibrotic effects were sustained for at least two weeks. Our findings demonstrate that human skin ex vivo is an appropriate model to assess the effects of fibrosis-inducing factors such as IGFBPs, and for evaluating the efficacy of inhibitors/therapies to halt the progression of fibrosis and potentially reverse it.
AB - Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology. A hallmark of SSc is fibrosis of the skin and internal organs. We recently demonstrated increased expression of IGFBP-3 and IGFBP-5 in primary cultures of fibroblasts from the skin of patients with SSc. In vitro, IGFBP-3 and IGFBP-5 induced a fibrotic phenotype and IGFBP-5 triggered dermal fibrosis in mice. To assess the ability of IGFBPs to trigger fibrosis, we used an ex vivo human skin organ culture model. Our findings demonstrate that IGFBP-3 and IGFBP-5, but not IGFBP-4, increase dermal and collagen bundle thickness in human skin explants, resulting in substantial dermal fibrosis and thickening. These fibrotic effects were sustained for at least two weeks. Our findings demonstrate that human skin ex vivo is an appropriate model to assess the effects of fibrosis-inducing factors such as IGFBPs, and for evaluating the efficacy of inhibitors/therapies to halt the progression of fibrosis and potentially reverse it.
UR - http://www.scopus.com/inward/record.url?scp=85056060320&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056060320&partnerID=8YFLogxK
U2 - 10.2174/1874312900802010017
DO - 10.2174/1874312900802010017
M3 - Article
AN - SCOPUS:85056060320
SN - 1874-3129
VL - 2
SP - 17
EP - 22
JO - Open Rheumatology Journal
JF - Open Rheumatology Journal
ER -